Skip to main content
Erschienen in: World Journal of Urology 3/2013

01.06.2013 | Original Article

The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis

verfasst von: Luca Cindolo, Caterina Fanizza, Marilena Romero, Luisella Pirozzi, Riccardo Autorino, Francesco Berardinelli, Luigi Schips

Erschienen in: World Journal of Urology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate differences in the risk of benign prostatic hyperplasia (BPH)-related hospitalization, for surgical and non-surgical reasons, and of new prostate cancer (PCa) diagnosis between patients using finasteride or dutasteride.

Methods

A retrospective cohort study was conducted using data from record linkage of administrative databases (pharmaceutical prescription data, hospital discharge records, Italian population registry). Men aged ≥40 years old who had received a prescription for at least 10 packs/year between January 1, 2004 and December 31, 2004 were included and followed for 5 years.
The association of the outcomes was assessed using a multiple Cox proportional hazard model. Propensity score-matched analysis and a 5–1, greedy 1:1 matching algorithm were performed.

Results

8,132 patients were identified. Overall incidence rates of BPH hospitalization and BPH-related surgery were 21.05 (95 % CI 19.52–22.71) and 20.97 (95 % CI 19.45–22.61) per 1,000 person-years, respectively. In the dutasteride group compared with finasteride group, the incidence rate of both events was statistically significant lower: 16.07 versus 21.76 for BPH hospitalization and 15.91 versus 21.69 for BPH-related surgery. The incidence rate of new PCa was also lower for the dutasteride group [8.34 (95 % CI 5.96–11.68) vs. 10.25 (95 % CI 9.15–11.49)]. Dutasteride was associated with a reduction in BPH-related hospitalizations (HR 0.75, 95 % CI 0.58–0.98 and 0.58–0.98 for surgical and non-surgical reasons). The matched analysis confirmed the risk reduction with dutasteride for BPH-related surgery.

Conclusions

These findings suggest that the clinical effects of dutasteride and finasteride might be different. Patients treated with dutasteride seem to be less likely to experience BPH-related hospitalization. Comparative studies are needed to confirm these results.
Literatur
1.
Zurück zum Zitat Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B (2008) Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 102:981–986PubMedCrossRef Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B (2008) Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 102:981–986PubMedCrossRef
3.
Zurück zum Zitat Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M (2004) 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45:620–626PubMedCrossRef Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M (2004) 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45:620–626PubMedCrossRef
4.
Zurück zum Zitat McConnell JD, Roehrborn CG, Bautista O et al (2003) Medical therapy of prostatic symptoms (MTOPS) research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398PubMedCrossRef McConnell JD, Roehrborn CG, Bautista O et al (2003) Medical therapy of prostatic symptoms (MTOPS) research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398PubMedCrossRef
5.
Zurück zum Zitat Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131PubMedCrossRef Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131PubMedCrossRef
6.
Zurück zum Zitat Robert G, Descazeaud A, de la Taille A (2011) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options? Curr Opin Urol 21:42–48PubMedCrossRef Robert G, Descazeaud A, de la Taille A (2011) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options? Curr Opin Urol 21:42–48PubMedCrossRef
7.
Zurück zum Zitat Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S (2004) Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 89:2179–2184PubMedCrossRef Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S (2004) Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 89:2179–2184PubMedCrossRef
8.
Zurück zum Zitat Naslund M, Black L, Eaddy M, Batiste LR (2007) Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs. Am J Manag Care 13:S17–S22PubMed Naslund M, Black L, Eaddy M, Batiste LR (2007) Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs. Am J Manag Care 13:S17–S22PubMed
9.
Zurück zum Zitat Naslund M, Regan TS, Ong C, Hogue SL (2008) 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives. Am J Manag Care 14:S148–S153PubMed Naslund M, Regan TS, Ong C, Hogue SL (2008) 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives. Am J Manag Care 14:S148–S153PubMed
10.
Zurück zum Zitat Issa MM, Runken MC, Grogg AL, Shah MB (2007) A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care 13:S10–S16PubMed Issa MM, Runken MC, Grogg AL, Shah MB (2007) A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care 13:S10–S16PubMed
11.
Zurück zum Zitat Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS (2011) Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: enlarged Prostate International Comparator Study (EPICS). BJU Int 108:388–394PubMedCrossRef Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS (2011) Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: enlarged Prostate International Comparator Study (EPICS). BJU Int 108:388–394PubMedCrossRef
12.
Zurück zum Zitat Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224PubMedCrossRef Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224PubMedCrossRef
13.
Zurück zum Zitat Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202PubMedCrossRef Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202PubMedCrossRef
14.
Zurück zum Zitat Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R (2011) The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med 365:97–99PubMedCrossRef Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R (2011) The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med 365:97–99PubMedCrossRef
15.
Zurück zum Zitat Margel D, Fleshner N (2012) The role of 5-alpha-reductase inhibitors in active surveillance. Curr Opin Urol 22:243–246PubMedCrossRef Margel D, Fleshner N (2012) The role of 5-alpha-reductase inhibitors in active surveillance. Curr Opin Urol 22:243–246PubMedCrossRef
16.
Zurück zum Zitat Cohen SA, Parsons JK (2012) Combination pharmacological therapies for the management of benign prostatic hyperplasia. Drugs Aging 29:275–284PubMedCrossRef Cohen SA, Parsons JK (2012) Combination pharmacological therapies for the management of benign prostatic hyperplasia. Drugs Aging 29:275–284PubMedCrossRef
17.
Zurück zum Zitat WHO Collaborating Centre for Drug Statistics Methodology (2003) ATC Index with DDDs. WHO, Oslo, Norway WHO Collaborating Centre for Drug Statistics Methodology (2003) ATC Index with DDDs. WHO, Oslo, Norway
19.
Zurück zum Zitat Monte S, Macchia A, Pellegrini F et al (2006) Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 27:2217–2223PubMedCrossRef Monte S, Macchia A, Pellegrini F et al (2006) Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 27:2217–2223PubMedCrossRef
20.
Zurück zum Zitat Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G (2007) The prognostic influence of chronic obstructive pulmonary disease in patients hospitalized for chronic heart failure. Eur J Heart Fail 9:942–948PubMedCrossRef Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G (2007) The prognostic influence of chronic obstructive pulmonary disease in patients hospitalized for chronic heart failure. Eur J Heart Fail 9:942–948PubMedCrossRef
21.
Zurück zum Zitat Macchia A, Monte S, Pellegrini F et al (2008) Depression worsens outcomes in elderly patients with heart failure: an analysis of 48,117 patients in a community setting. Eur J Heart Fail 10:714–721PubMedCrossRef Macchia A, Monte S, Pellegrini F et al (2008) Depression worsens outcomes in elderly patients with heart failure: an analysis of 48,117 patients in a community setting. Eur J Heart Fail 10:714–721PubMedCrossRef
22.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 40:373–383PubMedCrossRef
23.
Zurück zum Zitat Romano PS, Roos LL, Jollis JG (1993) Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46:1075–1079PubMedCrossRef Romano PS, Roos LL, Jollis JG (1993) Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46:1075–1079PubMedCrossRef
24.
Zurück zum Zitat D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281PubMedCrossRef D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281PubMedCrossRef
25.
Zurück zum Zitat Yanovitzky I, Zanutto E, Hornik R (2005) Estimating causal effects of public health education campaigns using propensity score methodology. Eval Program Plann 28:209–220CrossRef Yanovitzky I, Zanutto E, Hornik R (2005) Estimating causal effects of public health education campaigns using propensity score methodology. Eval Program Plann 28:209–220CrossRef
26.
Zurück zum Zitat Parsons LS (2004) Reducing bias in a propensity score matched pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. SAS Institute, Cary, NC, In Parsons LS (2004) Reducing bias in a propensity score matched pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. SAS Institute, Cary, NC, In
27.
Zurück zum Zitat Austin PC, Grootendorst P, Anderson GM (2007) A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 26:734–753PubMedCrossRef Austin PC, Grootendorst P, Anderson GM (2007) A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 26:734–753PubMedCrossRef
28.
Zurück zum Zitat Lin DY, Psaty BM, Krommal RA (1998) Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948–963PubMedCrossRef Lin DY, Psaty BM, Krommal RA (1998) Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948–963PubMedCrossRef
29.
Zurück zum Zitat McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. finasteride long-term efficacy and safety study group. N Engl J Med 338:557–563PubMedCrossRef McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. finasteride long-term efficacy and safety study group. N Engl J Med 338:557–563PubMedCrossRef
30.
Zurück zum Zitat Fenter TC, Runken MC, Black L, Eaddy M (2007) Finasteride versus dutasteride: a real-world economic evaluation. Am J Manag Care 13:S23–S28PubMed Fenter TC, Runken MC, Black L, Eaddy M (2007) Finasteride versus dutasteride: a real-world economic evaluation. Am J Manag Care 13:S23–S28PubMed
Metadaten
Titel
The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis
verfasst von
Luca Cindolo
Caterina Fanizza
Marilena Romero
Luisella Pirozzi
Riccardo Autorino
Francesco Berardinelli
Luigi Schips
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2013
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-012-1000-4

Weitere Artikel der Ausgabe 3/2013

World Journal of Urology 3/2013 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.